{"id":296417,"date":"2025-07-29T00:00:00","date_gmt":"2025-07-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0026-2023-biopharma-alzheimers-disease-current-treatment-treatment-algorithms-claims-data\/"},"modified":"2026-04-24T11:15:14","modified_gmt":"2026-04-24T11:15:14","slug":"algocg0026-2025-biopharma-alzheimers-disease-current-treatment-treatment-algorithms-claims-data-analysis-alzheimers","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0026-2025-biopharma-alzheimers-disease-current-treatment-treatment-algorithms-claims-data-analysis-alzheimers\/","title":{"rendered":"Alzheimer&#8217;s Disease &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Alzheimer&#8217;s Disease (US)"},"content":{"rendered":"<p>Until recently, approved treatments for Alzheimer\u2019s disease (<abbr title=\"Alzheimer's disease\">AD<\/abbr>) primarily consisted of approved procognitive symptomatic drugs (e.g., donepezil, memantine), as well as off-label antidepressants and atypical antipsychotics, to address behavioral and neuropsychiatric symptoms. However, the <abbr title=\"Alzheimer's disease\">AD<\/abbr> treatment landscape is shifting with the recent launches of <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>s, including Eisai \/ Biogen\u2019s lecanemab (Leqembi) and Eli Lilly\u2019s donanemab (Kisunla), for early <abbr title=\"Alzheimer's disease\">AD<\/abbr>. Additionally, Lundbeck \/ Otsuka\u2019s Rexulti became the first drug to approved by the <abbr title=\"Food and Drug Administration\">FDA<\/abbr> for agitation in <abbr title=\"Alzheimer's disease\">AD<\/abbr>. Numerous potential <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>s (e.g., Eisai \/ Biogen\u2019s subcutaneous lecanemab, Eli Lilly\u2019s remternetug, Roche\u2019s trontinemab, Novo Nordisk\u2019s semaglutide) and emerging neuropsychiatric treatments (e.g., Axsome\u2019s Auvelity, Karuna \/ <abbr title=\"Bristol Myers Squibb\">BMS<\/abbr>\u2019s Cobenfy) are in the pipeline. Established and emerging players must understand today\u2019s treatment landscape and patient journey to optimize future uptake and competitive positioning.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"Alzheimer's disease\">AD<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"Alzheimer's disease\">AD<\/abbr> patients?<\/li>\n<li>How have Adlarity and Rexulti been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of <abbr title=\"Alzheimer's disease\">AD<\/abbr> patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"Alzheimer's disease\">AD<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em> provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW141849310 BCX8 round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key drugs:<\/strong> Adlarity, donepezil, galantamine, memantine <abbr title=\"immediate release\">IR<\/abbr>, Namenda <abbr title=\"extended release\">XR<\/abbr>, Namzaric, rivastigmine, rivastigmine patch, atypical antipsychotics, Rexulti, Nuplazid, antidepressants<\/p>\n","protected":false},"template":"","class_list":["post-296417","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-therapy-areas-neurology","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296417\/revisions"}],"predecessor-version":[{"id":517632,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296417\/revisions\/517632"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}